Dexcom (DXCM) Cash & Equivalents (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash & Equivalents data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 23.57% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 23.57% increase from a year earlier, with the FY2025 full-year figure at $917.7 million, up 583.83% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.1 billion, up from $917.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for DXCM reached as high as $1.4 billion in Q3 2025 and fell as low as $134.2 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $814.0 million across 5 years, with a median of $735.4 million in 2022.
• Across the five-year window, Cash & Equivalents plunged 76.3% in 2024 and jumped 583.83% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $642.3 million in 2022, then fell by 11.83% to $566.3 million in 2023, then plunged by 76.3% to $134.2 million in 2024, then soared by 583.83% to $917.7 million in 2025, then advanced by 21.85% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.1 billion in Q1 2026, $917.7 million in Q4 2025, and $1.4 billion in Q3 2025.